BRAF and non-small cell lung carcinoma: Retrospective studies consistently report that ORRs for ICI monotherapy in BRAF mutant NSCLC patients vary between 10% to 30%, with median PFS times ranging from 2 to 4 months (22, 24, 25, 46, 47).